Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. — Dimosthenis Skarlos (2005) | RDL Network
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Article 2005 en
Authors
DS
Dimosthenis Skarlos
HK
Haralabos P. Kalofonos
GF
George Fountzilas
Abstract
1 min read
The combination of GEM and PLD in patients with AEOC, who are resistant/ refractory to platinum and/or Taxanes, did not show any superiority over monotherapy. However, in view of the acceptable toxicity profile, the above combination may deserve further investigation in a randomised setting.
Jim Janinis, George P. Stathopoulos, Paul Nikolaidis, Haralabos P. Kalofonos, Anna Kalogera‐Fountzila, E. Samantas, Gerasimos Aravantinos, Athanassios Anagnostopoulos, Christos Tolis, Thomas Makatsoris, S. Rigatos, Dimitrios Bafaloukos, Meletios A Dimopoulos, John Daniilidis, George Fountzilas
Dimitrios Bafaloukos, C. Papadimitriou, Helena Linardou, Gerasimos Aravantinos, Pavlos Papakostas, D. Skarlos, P. Kosmidis, George Fountzilas, Helen Gogas, Haralabos P. Kalofonos, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.